$SRPT — WATCHLIST 📊

$SRPT — WATCHLIST 📊 Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and o 🎯 Q2 2026 | Rev $1B | EPS $-3.58 vs $-0.77 🔴 💡 Consensus expected EPS of -0.77, actual was -3.58—a massive miss. Revenue guidance was maintained, suggesting operational performance may be in line. The market may have overreacted to the bottom-line miss, creating a potential opportunity if the loss does not signal a permanent increase in cash burn. 📉 Reward/risk: 2.09:1 🏢 Business Quality: 5/10 📊 Valuation: fair — based on implied market cap of ~$3–4B (assuming ~200M shares), P/S is 2.5–3x on guided revenue, which is reasonable for a revenue-generating... 🔮 Catalyst: Next quarterly report or an analyst day clarifying expense outlook 📊 Our read: WATCHLIST. Full analysis → https://stockduty.xyz/s/SRPT0624

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and o